According to a new report from Intel Market Research, the global Oligo Synthesis market was valued at $639 million in 2024 and is projected to reach $1,435 million by 2032, growing at an impressive CAGR of 12.5% during the forecast period (2025–2032). This growth is driven by accelerating advancements in genetic research, expanding applications in therapeutics, and rising demand for synthetic DNA/RNA across multiple industries.
📥 Download FREE Sample Report:
Oligo Synthesis Market - View in Detailed Research Report
Oligonucleotide synthesis (Oligo synthesis) refers to the chemical process of creating short sequences of nucleic acids (DNA or RNA) with defined structures. These oligos—typically under 100 bases in length—serve as essential tools in molecular biology, functioning as primers for PCR amplification, probes for diagnostics, and building blocks for synthetic biology applications. The technology enables precise control over nucleotide sequences, allowing researchers to incorporate modifications like fluorescent tags or chemical alterations for specialized applications.
Modern oligo synthesis has become indispensable for:
📥 Download FREE Sample Report:
Oligo Synthesis Market - View in Detailed Research Report
The rise of precision medicine has created unprecedented demand for custom oligonucleotides. With over 500 oligonucleotide-based drugs in clinical pipelines (including mRNA vaccines, siRNA, and antisense therapies), pharmaceutical companies are increasingly partnering with synthesis providers to accelerate drug development. The success of COVID-19 mRNA vaccines has further validated the potential of synthetic nucleic acids in therapeutics.
The CRISPR revolution continues to fuel market growth, as researchers require highly specific guide RNAs (gRNAs) and donor DNA templates for genome engineering. The global gene editing market's expansion to $15 billion+ by 2030 directly correlates with rising oligo synthesis demand. New applications in agriculture (GMO development) and industrial biotechnology are creating additional growth avenues.
Leading manufacturers are implementing high-throughput synthesis platforms and AI-driven sequence design tools to improve yield and reduce costs. Companies like Twist Bioscience have demonstrated how scalable silicon-based DNA synthesis can achieve price points previously considered impossible, democratizing access to synthetic biology tools.